Pharma Journalist -

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure – affecting more than 250 million people…
Read More...

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B…
Read More...

Capsida Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class…
Read More...

Novo Nordisk announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance…
Read More...

 BioNTech SE and CureVac N.V. announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)…
Read More...

One of the most valuable aspects of the Microbiome Movement Summit is its emphasis on meaningful connections. With over 8 hours of structured networking built into the agenda, attendees…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of…
Read More...

YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the U.S. Food and Drug Administration (FDA) has cleared the…
Read More...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the…
Read More...